Results 121 to 130 of about 9,252,196 (204)

Engineering a High-Affinity Monoclonal Antibody for Thiram Immunoassays and Protection. [PDF]

Small
Lu L, Jiang K, Li N, Li X, Madushika L, Ling S, Wang S.   +6 more
europepmc   +1 more source

Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. [PDF]

Cells
Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, Ghiringhelli F.   +6 more
europepmc   +1 more source

Systematic validation of graph neural network explanations against adverse outcome pathway reactive centers for skin sensitization. [PDF]

J Cheminform
Jeon B.
europepmc   +1 more source

Synthesis, Characterization, and Structural Aspects of a Novel Benzo[<i>b</i>]fluoranthene Hapten for PAHs. [PDF]

ACS Omega
Wu X, Zhao J, Zhou Z, Zhang X, Geng F, Huang Z, Li Y, Xiong X, Liu Y.   +8 more
europepmc   +1 more source

Fabrication and optimization of a hybrid 3D-printed flexible electrochemical biosensor for sensitive detection of 1-hydroxypyrene glucuronide, an associated wildfire exposure biomarker. [PDF]

Talanta
Fu Y, Chen C, Li X, Song Y, Simpson CD, Naeher LP, Qiu K, Du D.   +7 more
europepmc   +1 more source

Discovery, Structural Characterization, and Preclinical Evaluation of Monoclonal Antibodies against Xylazine Poisoning. [PDF]

ACS Pharmacol Transl Sci
Kang J, Xu R, Lee S, Luengas D, Kim CM, Marecki C, Gallant J, Moeller N, Shi K, Jahan R, Hicks D, Runyon S, Aihara H, Pravetoni M.   +13 more
europepmc   +1 more source

Localized Facial Bullous Eruption Following Iodinated Contrast in a Patient With Renal Failure. [PDF]

Cureus
Zhang JR, Cherner A, Cox MW, Shokrzadeh CL.   +3 more
europepmc   +1 more source

Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins. [PDF]

Toxicol Sci
Grice S, Albashtawy S, Wells G, Hering L, Adair K, Sarsby J, Brownridge P, Ford M, Lloyd R, Hampson L, Wagner A, Sun Y, Liu H, Hammond S, Meng X, Zhang F, Naisbitt D.   +16 more
europepmc   +1 more source

Engineered antibodies that stabilize drug-modified KRAS^G12C neoantigens enable selective and potent cross-HLA immunotherapy. [PDF]

Nat Commun
Maso L, Mosure SA, Rodriguez-Aponte SA, Pizzo A, Mensah DN, Southard M, Sze S, Ahmed T, Vash B, Hattori T, Rajak E, Koide A, Neel BG, Koide S, Liu W, Toenjes ST, Jardine PDS, Chopra R, Rader C, Stopfer LE.   +19 more
europepmc   +1 more source

Current and emerging new approach & methodologies for skin hazard assessment. [PDF]

Toxicol Res
Shin SY, Lim KM.
europepmc   +1 more source